1.91

0.26% -0.005

After Hours: 1.90 -0.01 -0.52%

Aadi Bioscience Inc (AADI)

Overview News Price History Option Chain Financials Why AADI Down? Discussions Forecast Stock Split

Aadi Bioscience Inc stock is currently priced at $1.91, with a 24-hour trading volume of 91,552. It has seen a -0.26% decreased in the last 24 hours and a +4.95% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.89 pivot point. If it approaches the $1.94 resistance level, significant changes may occur.

Previous Close:

$1.915

Open:

$1.93

24h Volume:

91,552

Market Cap:

$46.90M

Revenue:

$23.26M

Net Income/Loss:

$-63.41M

P/E Ratio:

-0.7828

EPS:

-2.44

Net Cash Flow:

$-64.56M

1W Performance:

+7.30%

1M Performance:

+4.95%

6M Performance:

-59.45%

1Y Performance:

-73.82%

1D Range:

$1.89

$1.93

52W Range:

$1.55

$8.60

Aadi Bioscience Inc Stock (AADI) Company Profile

Name

Aadi Bioscience Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

424 473 8055

Address

17383 Sunset Boulevard, Suite A250, Pacific Palisades

Employee

Twitter

Next Earnings Date

2024-06-11

Latest SEC Filings

AADI's Discussions on Twitter

Aadi Bioscience Inc Stock (AADI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-11-22	Initiated	Jefferies	Buy
Oct-01-21	Initiated	Cowen	Outperform
Sep-14-21	Initiated	Ladenburg Thalmann	Buy
Sep-08-21	Initiated	Piper Sandler	Overweight

Aadi Bioscience Inc Stock (AADI) Latest News

Analysts Set Expectations for Aadi Bioscience, Inc.'s Q2 2024 Earnings (NASDAQ:AADI) - Defense World

Defense World

Aadi Bioscience, Inc. (NASDAQ:AADI) Expected to Earn FY2025 Earnings of ($3.10) Per Share - Defense World

Defense World

Aadi Bioscience (NASDAQ:AADI) Receives Neutral Rating from HC Wainwright - Defense World

Defense World

Aadi Bioscience, Inc. (NASDAQ:AADI) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance

Yahoo Finance

Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI) - Simply Wall St

Simply Wall St

Analysts Just Made A Major Revision To Their Aadi Bioscience, Inc. (NASDAQ:AADI) Revenue Forecasts - Yahoo Finance

Yahoo Finance

Aadi Bioscience Inc Stock (AADI) Financials Data

Aadi Bioscience Inc (AADI) Revenue 2024

AADI reported a revenue (TTM) of $23.25 million for the quarter ending September 30, 2023, a +111.62% rise year-over-year.

Aadi Bioscience Inc (AADI) Net Income 2024

AADI net income (TTM) was -$63.41 million for the quarter ending September 30, 2023, a -1.31% decrease year-over-year.

Aadi Bioscience Inc (AADI) Cash Flow 2024

AADI recorded a free cash flow (TTM) of -$64.56 million for the quarter ending September 30, 2023, a -27.20% decrease year-over-year.

Aadi Bioscience Inc (AADI) Earnings per Share 2024

AADI earnings per share (TTM) was -$2.36 for the quarter ending September 30, 2023, a +20.81% growth year-over-year.

Aadi Bioscience Inc Stock (AADI) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Desai Neil	EXECUTIVE CHAIRMAN	Apr 02 '24	Sale	2.23	22,228	49,513	1,371,543
Desai Neil	EXECUTIVE CHAIRMAN	Apr 01 '24	Sale	2.31	17,772	41,101	1,393,771
Desai Neil	EXECUTIVE CHAIRMAN	Mar 04 '24	Sale	2.10	14,964	31,415	1,411,543
Desai Neil	EXECUTIVE CHAIRMAN	Mar 01 '24	Sale	1.97	27,036	53,226	1,426,507
Desai Neil	Executive Chairman	Feb 01 '24	Sale	1.74	42,000	73,269	1,453,543
Desai Neil	Executive Chairman	Jan 02 '24	Sale	2.06	42,000	86,549	1,495,543
Desai Neil	Executive Chairman	Dec 06 '23	Sale	4.82	7,037	33,914	1,537,543
Desai Neil	Executive Chairman	Dec 05 '23	Sale	5.02	15,740	78,941	1,544,580
Desai Neil	Executive Chairman	Dec 04 '23	Sale	5.15	10,876	55,986	1,560,320
Desai Neil	Executive Chairman	Dec 01 '23	Sale	5.14	8,347	42,881	1,571,196

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, ABI-009 (FYARRO) is a form of sirolimus bound to albumin. Aadi is evaluating ABI-009 in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was founded in 2011 and is headquartered in Pacific Palisades, California.